Wire · opportunities
Solid Tumor Therapeutics New Approvals and Guidelines
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 October 2026 · Fusion42 review
New therapeutic approvals and guideline updates for solid tumors, including several targeted therapies for non-small cell lung cancer (NSCLC) with specific genetic mutations, emphasize the growing role of precision medicine. The 2024 ASCO guidance endorses germline genetic testing to prioritise targeted treatments, supporting the use of FDA-approved tests to identify mutations for these new agents.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to integrate genetic testing into your diagnostic process to access new lung cancer therapies. Delaying mutation profiling risks missing approved targeted treatments that require FDA-approved tests for patient eligibility.
◆ Coverage
1 source · 13 Oct 2026
◆ Related on Wire
◆ Topics